This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.—
We were interested in the recent report of Nutt et al in the Archives (35:810-811, 1978) describing the failure of naltrexone to affect the conditions of patients with Parkinson's disease. We also found that naloxone hydrochloride, another potent opiate antagonist, has no obvious effect on the major manifestations of Parkinson's disease, on the therapeutic benefit of levodopa, or on levodopainduced dyskinesias. Four patients with idiopathic Parkinson's disease were given 0.8 mg of intravenous (IV) naloxone hydrochloride and a fifth patient was given 2 mg of IV naloxone hydrochloride. There was no subsequent change in tremor (evident in three patients), rigidity, akinesia, or posture. All patients had taken levodopa, usually with carbidopa (Sinemet), two to three hours earlier, but the manifestations of their Parkinson's disease were only partially reversed; there was neither an improvement nor a deterioration after administration of naloxone hydrochloride. Freezing episodes continued in two patients in
Price P, Baxter RCH, Parkes JD, Marsden CD. Opiate Antagonists and Parkinson's Disease. Arch Neurol. 1979;36(10):661. doi:10.1001/archneur.1979.00500460095021
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: